在国际大型会议担任主席、特邀报告和口头报告:

1. Huang H*. The report of transplantation in China in five recent year. (第22届亚太地区骨髓移植会议)(特邀报告)(October 28-30, 2017, Tehran, Iran).

2. Huang H*. Advanced CD19-CART therapy for acute lymphocytic leukemia and B cell lymohoma/ China Perspective. (第22届亚太地区骨髓移植会议)(特邀报告)(October 28-30, 2017, Tehran, Iran).

3. Huang H*. Haploidentical hematological stem cell transplantation as a front line therapy for adult Acute Lymphocytic Leukemia.  (第22届亚太地区骨髓移植会议)(特邀报告)(October 28-30, 2017, Tehran, Iran).

4. Huang H*. Management of CD19-targeted CAR-T Associated Complications. 43th Annual Meeting of the European Group for Blood and Marrow Transplantation2017.3.26-3.29, Marseille, France(特邀报告).

5. Huang H*. CAR-T cells post allo-transplant: practical considerations. The winter workshop of 43th Annual Meeting of the European Group for Blood and Marrow Transplantation. November 26, 2016, Marseille, France. (特邀报告)

6. Huang H*. Emerging Cellular Therapies-CART cell in Hematological malignant disease. The 21th Congress of Asia-Pacific Blood and Marrow Transplantation. (第21届亚太地区骨髓移植会议)(特邀报告)(October 28-30, 2016, Singapore).

7. Hu Y,  Huang H*. Superiior therapeutic efficacy of CART19 over chemotherapy in relapsed/refractory ALL patients. 21th Congress of the Asia-Pacific Blood and Marrow Transplantation. (第21届亚太地区骨髓移植会议)(口头报告)(October 28-30, 2016, Singapore).

8. Wang B, Shan W, Liu S, Lin Y, Zhang H, Zhu N ,  Cai S ,  Yu X , Huang H*. TSC-mTOR Signaling Pathway Regulates the Immunogenicity of Bone Marrow Mesenchymal Stem Cells in Inflammatory Microenvironment. Bone Marrow Transplant. 51(suppl 1): S64. 42th Annual Meeting of the European Group for Blood and Marrow Transplantation, 2016.4.3-4.6, Valencia, SPAIN. 第42届欧洲血液与骨髓移植年会,口头报告

9. Hu Y , Wu Z , Luo Y , Shi J, Pu C , Wei G , Sun J , Yu J, Xiao L, Huang H*. Safety and Efficacy of CD19 Chimeric Antigen Receptor-Modified T Cells for Relapsed/Refractory Acute Lymphocytic Leukemia Under Fludarabine and Cyclophosphamide based Lymphodepletion. Bone Marrow Transplant. 51(suppl 1): S99-100. 42th Annual Meeting of the European Group for Blood and Marrow Transplantation, 2016.4.3-4.6, Valencia, SPAIN. 第42届欧洲血液与骨髓移植年会,口头报告

10. Huang H*. Current States of Stem Cell Transplantation in China.Catholic .2015中韩慢粒研讨会, 2015.3.27, Seoul, Korea, 特邀报告

11. Huang H*. Biological Advances in Leukemia Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation. 第19届亚太地区骨髓移植会议, 2014.11.16-19, Hangzhou, China, 特邀报告

12. Sheng L, Fu H, Hu Y, Luo Y, Lai X, Tan Y, Shi J, Fu S, He Y, Huang H*.Impaired NK cells cytotoxicity against activated, alloreactive donor T cells in aGVHD can be corrected by dasatnib ex vivo. 第19届亚太地区骨髓移植会议, 2014.11.16-19, Hangzhou, China, 口头报告

13. Xiao H, Luo Y, Wang L-M, Lai X, Shi J, Tan Y, Fu S, Wang Y, He J, Xie W, Zheng W, Ye X, Yu X, Cai Z, Lin M, Huang H*. Exome Sequencing of Adult Philadephia Chromosome-Negative Acute Lymphoblastic Leukemia from Diagnosis to Relapse after Allogeneic Hematopoietic Cell Transplantation Reveals Novol Mutated Genes and Clonal Evolution. 第19届亚太地区骨髓移植会议, 2014.11.16-19, Hangzhou, China, 口头报告

14. Luo Y, Xiao H, Lai X, Shi J, Tan Y, He J, Xie W, Zheng W, Zhu Y, Ye X, Cai Z, Lin M and Huang H*. Prospective evaluation of T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with contemporaneous matched sibling HSCT and unrelated HSCT: results from an open-label trial. 第40届欧洲血液与骨髓移植年会, 2014.3.30-4.2, Milan, Italy, 口头报告

15. Xiao H, Huang H*. Genomic Evolution and Genetic Alterations in Adult Patients with Philadephia Chromosome-negative Acute Lymphoblastic Leukemia from Diagnosis to Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. 第40届欧洲血液与骨髓移植年会, 2014.3.30-4.2, Milan, Italy, 口头报告

16. Wang Y, Zhang L, Liu S, Huang H*. Defining Molecular Roadblocks through an Intermediate Standstill Derived during Reprogramming Human Fibroblast to iPS Cell. 第40届欧洲血液与骨髓移植年会, 2014.3.30-4.2, Milan, Italy, 口头报告

17. Hu K, Gu Y, Lou L, Liu L, Hu Y, Fu S, Wang B, Yu X, Huang H*. Bone marrow mesenchymal stromal cells protect acute leukemia cells from cytotoxic agents via galectin-3 mediated Wnt/β-catenin signaling. 第40届欧洲血液与骨髓移植年会, 2014.3.30-4.2, Milan, Italy, 口头报告

18. Xiao H, Luo Y, Lai X, Shi J, Tan Y, He J, Xie W, Zheng W, Wang L, Fu S, Wang Y, Ye X, Yu X, Cai Z, and Huang H*. Whole-exome Sequencing of Adult Philadephia-negative Acute Lymphoblastic Leukemia from Diagnosis to Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Reveals Clonal Evolution and Relapse-associated Mutated Genes. Blood.2013.122:156. 第55届美国血液学年会, 2013.12.7-10, New Orleans, USA, 口头报告         

19. Zhang M, Luo Y, Lai X, Tan Y, Zheng W, Zhu Y, Shi J, and Huang H*. Minimal residual disease levels at time of CR1 and transplant predict outcome in Philadephia chromosome-negative adult ALL. Blood.2013.122:713. 第55届美国血液学年会, 2013.12.7-10, New Orleans, USA, 口头报告

20. Huang H*. Biology, Prevention and Treatment of Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. 第18届亚太地区骨髓移植会议, 2013.11.1-4, Ho Chi Ming City, Vietnam, 特邀报告

21. Du K, Huang H*. A signal center analysis of Philadephia chromosome-positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in imatinib era. 第18届亚太地区骨髓移植会议, 2013.11.1-4, Ho Chi Ming City, Vietnam, 口头报告

22. Shi J, Huang H*. Epidemiology of invasive fungal infections in allogeneic stem cell transplantation recipients: risk factors for infection according to time after transplantation. 第18届亚太地区骨髓移植会议, 2013.11.1-4, Ho Chi Ming City, Vietnam, 口头报告

23. Hu Y, Huang H*. Reduced frequency of FOXP3+ gammadeta TCR+ regulatory T cells in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. 第18届亚太地区骨髓移植会议, 2013.11.1-4, Ho Chi Ming City, Vietnam, 口头报告

24. Tan Y, Huang H*.Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients post allogeneic hematopoietic stem cell transplantation. 第18届亚太地区骨髓移植会议, 2013.11.1-4, Ho Chi Ming City, Vietnam, 口头报告

25. Hu Y, Luo Y, Shi J, Tan Y, Zheng W, Cai Z, Huang H*.HBsAg- recipients had comparable outcomes and acquired HBV-specific humoral immunity after haematopoietic stem cell transplantation from HBsAg+ donors. Bone Marrow Transplant. 48(suppl 2): S29.第39届欧洲血液与骨髓移植年会, 2013.4.7-10, London, UK, 口头报告

26. Xiao H, Luo Y, Lai X, Fu S, Shi J, Tan Y, He J, Xie W, Zheng W, Wang L, ZhangL, Liu L, Ye X, Yu X, Cai Z, Lin M, Huang H*.Genetic variations in graft-versus-leukemia reaction pathways and relapse risk after allogeneic hematopoietic stem cell Transplantation: an explore study. 美国国立卫生研究院第二届国际造血干细胞移植后复发工作会议, 2012.11.5-6, Washington, USA, 口头报告

27. Huang H*. Allogeneic transplantation in AML-CR1 in era of molecular markers. 第17届亚太地区骨髓移植会议, 2012.10.26-28, Hyderabad, India, 特邀报告

28. Xiao H, Luo Y, Lai X, Fu S, Shi J, Tan Y, He J, Xie W, Zheng W, Wang L, Zhang L, Liu L, Ye X, Yu X, Cai Z, Lin M, Huang H*Genetic variations in Toll-like receptors and acute GVHD in allogeneic hematopoietic stem cell transplantation. 第17届亚太地区骨髓移植会议, 2012.10.26-28, Hyderabad, India, 口头报告 

29. Hu Y, Gu Y, Wu K, Sheng L, Huang H*.Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-versus-host disease in cyclophosphamide and anti-CD122 conditioned NOD/SCID mice. 第17届亚太地区骨髓移植会议, 2012.10.26-28, Hyderabad, India, 口头报告

30. Xiao H, Luo Y, Lai X, Fu S, Shi J, Tan Y, He J, Xie W, Zheng W, Wang L, Zhang L, Liu L, Ye X, Yu X, Cai Z, Lin M, Huang H*. Persistent cytomegalovirus reactivation and cytomegalovirus UL97 mutations in the seropositive haematopoietic stem cell transplantation setting. Bone Marrow Transplant. 47(suppl 2): S25.第38届欧洲血液与骨髓移植年会, 2012.4.1-4, Geneva, Switzerland, 口头报告

31. Hu Y, Gu Y, Sheng L, Wu K, Shi J, Tan Y, Yu X, and Huang H *. Decitabine -conditioned regulatory gamma delta T Cells provide enhanced protection from graft-versus-host disease via improved Foxp3 stability and ICOS up-regulation. Bone Marrow Transplant. 47(suppl 2): S72. 第38届欧洲血液与骨髓移植年会, 2012.4.1-4, Geneva, Switzerland, 口头报告

32. Wu KN, Hu YX, Fu HR, Sheng LX, and Huang H*. Ex Vivo-Expanded gamma deltaT Cells Can Efficiently Kill Human Acute Myeloid Leukemia Cells Via Trogocytosis. Blood.2011.118: 580. 第53届美国血液学年会, 2011.12.10-13, San Diego, USA, 口头报告         

33. Huang H*. Biological advances and intervention in leukemia relapse following allogeneic hematopoietic stem cell transplantation. 第16届亚太地区骨髓移植会议, 2011.10.30-11.2, Sydney, Australia, 特邀报告

34. Xiao H, Luo Y, Shi J, Tan Y, He J, Xie W, Lai X, Yu X, Cai Z, Lin M, Ye X,Huang H*. Donor Natural Killer Cell Activating Gene Polymorphisms Associated with the Risk of Early Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. 第16届亚太地区骨髓移植会议, 2011.10.30-11.2, Sydney, Australia, 口头报告

35. Huang H*. Plasma Proteins: New Biomarkers in the Diagnosis and Treatment of   Complications of Allogeneic Hematopoietic Stem Cell Transplantat. 第7届中日生命科学研讨会, 2011.11.23-24, Kumamoto, Japan, 特邀报告

36. Xu Y, Huang H*. Induction of Hematopoietic Commitment from Adult Human Bone Marrow Mesenchymal Stem Cell-derived Induced Pluripotent Stem Cells with Cytokines. 第16届亚太地区骨髓移植会议, 2011.10.30-11.2, Sydney, Australia, 口头报告

37. Xiao H, Luo Y, Shi J, Tan Y, He J, Xie W, Lai X, Yu X, Cai Z, Lin M, Ye X,Huang H*. Donor selection for natural killer cell activating genes leads to a reduced rate of relapse after allogeneic hematopoietic cell transplantation both for acute myeloid leukemia and acute lymphoblastic leukemia. Bone Marrow Transplant. 46(suppl 2): S73.第37届欧洲血液与骨髓移植年会, 2011.4.3-6, Paris, France, 口头报告

38. Xiao H, Luo Y, Shi J, Tan Y, He J, Xie W, Lai X, Yu X, Cai Z, Lin M, Ye X,Huang H*. Association between genetic variants in T-cell costimulatory molecule and outcome after unrelated hematopoietic cell transplantation. Bone Marrow Transplant. 46(suppl 2): S18.第37届欧洲血液与骨髓移植年会, 2011.4.3-6, Paris, France, 口头报告

39. Xiao H, Lai X, Luo Y, Shi J, Tan Y, He J, Xie W, Zhang L, Wang Y, Cai Z, Lin M,Ye X, Huang H*.T-cell costimulatory molecule genotypes are associated with the risk of early cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2011.17(2)(suppl 2):S156. 2011年美国血液学会骨髓移植年会, 2011.2.17-21, Honolulu, USA, 口头报告

40. Xiao H, Lai X, Luo Y, Shi J, Tan Y, He J, Xie W, Zhang L, Wang Y, Cai Z, Lin M, Ye X, and Huang H*. The Genotype of T-cell Costimulatory Molecule is Associated with Relapse Incidence in Patients with Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. Blood.2010; 116(21): 301 第52届美国血液学年会, 2010.12.4-7, Orlando, USA, 口头报告         

41. Huang H*. Recent advances and choices of transplantation conditioning regimen.第15届亚太地区骨髓移植会议, 2010.10.28-31, Phuket, Thailand, 主席, 特邀报告

42. Xiao H, Zhu X, Cao W, Lai X, Luo Y, Shi J, Tan Y, He J, Xie W, Zhang L, WangY, Cai Z, Lin M, Ye X, and Huang H*. Effect of low-dose, short-course mycophenolate mofetil as GVHD prophylaxis and study of the polymorphisms of target gene of mycophenolate mofetil. 第15届亚太地区骨髓移植会议, 2010.10.28-31, Phuket, Thailand, 口头报告, 口头报告二等奖

43. Xiao H, Lai X, Luo Y, Shi J, Tan Y, He J, Xie W, Meng X, Zheng G, Han X, Yu X,Cai Z, Lin M, Ye X, Huang H*.Donor and recipient TGF-beta 1 gene polymorphisms are associated with the risk of early cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant. 45(suppl 2): S37.第36届欧洲血液与骨髓移植年会, 2010.3.21-24, Vienna, Austria, 口头报告

44. Huang H*. New advances in the research of graft-versus-host disease after allo-HSCT. 2010年台湾血液学年会, 2010.4.9, Taiwan, 特邀报告

45. Huang H*. Cross-Straits Summit in Managing Acute Leukemia: Challenges and Options in 2010 and Beyond. 2010年台湾血液学年会, 2010.4.9, Taiwan, 主席

46. Huang H*. Reduced intensity transplantation: current role and future prospects. 第一届东亚血液学联盟会议, 2010.4.22-24, Kuala Lumpur, Malaysi, 特邀报告

47. Huang H*. Transplantation in autoimmune disease. 第一届东亚血液学联盟会议, 2010.4.22-24, Kuala Lumpur, Malaysi, 特邀报告

48. Huang H*. China consensus of CML treatment 2010. 2010年亚太慢性粒细胞白血病顾问委员会会议, 2010.4.25, Kuala Lumpur, Malaysi, 特邀报告

49. Huang H*. Advance of mesenchymal stem cell research and application in clinic.第4届西澳分子与细胞治疗论坛, 2010.4.26-5.7, The University of Western Australia, 特邀报告

50. Huang H*. Prophylaxis and treatment of graft-versus-host disease following allo-HSCT. 第14届亚太地区骨髓移植会议, 2009.8.27-29, Seoul, Korea, 主席, 特邀报告

51. Xiao H, Lai X, Luo Y, Shi J, Tan Y, He J, Xie W, Meng X, Zheng G, Han X, Yu X, Cai Z, Lin M, Ye X, Huang H*Association between tumor necrosis factor-α gene polymorphisms and acute graft-versus-host disease in unrelated donor allogeneic haematopoietic stem cell transplantation in Chinese population. 第14届亚太地区骨髓移植会议, 2009.8.27-29, Seoul, Korea, 口头报告

52. Lai X, Huang H*, Huang L, Cao J, Zeng F, Zheng J. Identification and enrichment of human bone marrow derived mesenchymal stem cells by monoclonal antibody, ZUC3. Bone Marrow Transplant. 41(suppl.1):S16. 第34届欧洲血液与骨髓移植年会, 2008.3.30-4.2, Flroence, Italy, 口头报告

53. Huang H*, Fan J, Lai X, Yu Q, Ding W, Wang Y. Intracerebral transplantation of human mesenchymal stem cells after hypoxic-ischemic brain damage in rat. Bone Marrow Transplant. 41(suppl.1):S16.第34届欧洲血液与骨髓移植年会, 2008.330-4.2, Flroence, Italy, 口头报告

54. Huang H*. Allogeneic Transplantation for Acute Lymphoblastic Leukemia. 2007年美国血液肿瘤治疗进展研讨会, New York, USA, 特邀报告

55. Huang H*. Treatment Strategies for Adult Acute Lymphoblastic Leukemia: Unrelated Donor Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in First Complete Remission. 第12届亚太地区骨髓移植会议, 2007.9, Beijing, China, 特邀报告

56. Huang H*. Unrelated Donor Hematopoietic Stem Cell Transplantation for 128 Patients with Hematological Malignancy. 第11届亚太地区骨髓移植会议, 2006.10, Nagoya, Japan, 口头报告

57. Huang H*. Unrelated Donor Hematopoietic Stem Cell Transplantation for Leukemia and Myelodysplastic Syndrome. 2006年亚太骨髓捐献者登记组织会议, 2006.4, Taiwan, 特邀报告

58. Huang H*. Unrelated Donor Hematopoietic Stem Cell Transplantation for Leukemia and Myelodysplastic Syndrome. 第10届亚太地区骨髓移植会议, 2005.10, Hangzhou, China, 特邀报告